Immunotherapy Archives

News and Trends 27 Aug 2015

Dutch Immuno-Oncology company raises Massive Series C Financing round

Sofinnova Ventures and Novo A/S step into one of the biggest European series C financing rounds, which is about €72.8 million. The money goes to the Dutch immuno-oncology company Merus and will advance its cancer-fighting bispecific antibodies. Back in April, Merus announced its intention to go public at the Nasdaq, with the goal of raising […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 […]

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche just dropped a first-generation antibody-based treatment preventing cancer cells from proliferating. Interestingly enough, the partner of the collaboration, Wilex’ subsidiary Heidelberg Pharma, stated the research “progressed well, on schedule, and in a mutually satisfactory manner”. What happened? Heidelberg Pharma is a German company that discovers new drugs using its platform technology for antibody drug […]

August 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

The massive expansion of AstraZeneca’s pipeline continues, as its biological subsidiary, MedImmune buys Inovio Pharmaceuticals‘ clinical-stage cancer vaccine that targets cancer caused by the human papillomavirus (HPV). MedImmune, which makes up nearly 50% of AstraZeneca’s pipeline, may spend over $720M (€653M) to bolster its cancer-associated portfolio. HPV is the most commonly sexually transmitted virus and […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 5 Aug 2015

Did Bavarian Nordic cheat on its clinical results?

The hedge fund Kerrisdale Capital just published a report explaining its position in Bavarian Nordic, showing that the Danish company’s lead candidate has ineffective results. Kerrisdale is inviting other investors to leave their shares in the company before it’s too late. Bavarian Nordic is under attack! Kerrisdale Capital, an hedge fund with track records in […]

August 5, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Jul 2015

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

Immunocore Limited, just announced that it has secured a £205 million financing (€293 m) from private investors to push forward its T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune diseases. This substantial amount of cash not only embodies the largest private investment ever made in Europe by a biotech company, but also the second […]

July 16, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

Kiadis launches its Cell-based Immunotherapies on European stock markets

Kiadis Pharma has launched an IPO on Euronext Amsterdam and Euronext Brussels with the aim of raising €32.7M. The company will invest the money in two cell-based immunotherapies for blood cancer and inherited blood disorders. Kiadis has filed for an Initial Public Offering on the Dutch and Belgian exchange markets. The money raised on the […]

July 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Dutch Immuno-Oncology company raises Massive Series C Financing round

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Roche abandons Wilex to Make Way for Immuno-Oncology

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Did Bavarian Nordic cheat on its clinical results?

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

CureVac’s mRNA Therapy is Working Against Prostate Cancer

Kiadis launches its Cell-based Immunotherapies on European stock markets

Lilly Cooperates with Immunocore to Fight Skin Cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!